Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q99726
UPID:
ZNT3_HUMAN
Alternative names:
Solute carrier family 30 member 3; Zinc transporter 3
Alternative UPACC:
Q99726; Q8TC03
Background:
The Probable proton-coupled zinc antiporter SLC30A3, also known as Solute carrier family 30 member 3 and Zinc transporter 3, plays a crucial role in maintaining zinc ion homeostasis in the brain. It functions by mediating the import of zinc from the cytoplasm into synaptic vesicles, highlighting its importance in neural communication and overall brain health.
Therapeutic significance:
Understanding the role of Probable proton-coupled zinc antiporter SLC30A3 could open doors to potential therapeutic strategies. Its pivotal function in zinc ion homeostasis within the brain underscores its potential as a target for addressing neurological conditions.